Surgical and oncological advances in the treatment of esophageal cancer

Takefumi Ohga, Yasue Kimura, Motonori Futatsugi, Mitsuhiro Miyazaki, Hiroshi Saeld, Tadahiro Nozoe

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Chemoradiotherapy (CR) and hyperthermochemoradiotherapy (HCR) have been performed on numerous patients with esophageal cancer. These neoadjuvant therapies for esophageal cancer are done widely. The purpose of this study is to demonstrate the recent advances in surgical and oncological treatment. Methods. From 1967 to 2000, 847 patients who underwent an esophagectomy were classified into 4 groups according to the date of operation. Group 1 consisted of 110 patients who underwent an esophagectomy in the first 10-year period (1967-1976), group 2 consisted of 194 patients who had operations from 1977 to 1986, group 3 comprised 400 patients who had operations from 1987 to 1996, and group 4 comprised 143 patients who had operations from 1997 to 2000. From 1967 to 2000, 322 patients with neoadjuvant therapy and esophagectomy were classified into 6 groups according to the kinds of anitcancer drugs that were administered. Group A received regimen A, using BLM (5 mg iv) 6 times as the chemotherapeutic drug in the early period (1965-1990); group B received regimen B, using cis-diaminedichloroplatinum (CDDP) (40 mg/m2) 3 times as the chemotherapeutic drug in the second period (1990-1997); and group C received regimen C, using CDDP (40 mg/m2) and 5FU (250 mg/m2) daily in the most recent period (1997-2000). The HCR group was also divided into the following 3 groups: Group D, who received regimen A and hyperthermia 6 times in the early period; group E, who received regimen B and hyperthermia 6 times in the next period; and group F, who received regimen C and hyperthermia 6 times in the most recent period. The local response and the longterm results were investigated. Results. A complete removal of the primary tumor was achieved in 29%, 39%, 62%, and 68% of the patients in groups 1, 2, 3, and 4, respectively. The 30-day operative mortality rates were 11%, 4%, 1%, and 0% in groups 1, 2, 3, and 4, respectively. The 5-year survival rates for all patients in groups 1, 2, and 3 were 16.7%, 19.2%, and 44.4%, respectively. The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 8 (66.7%) in group C, 79 (63.7%) in group D, 36 (73.5%) in group E, and 12 (75.0%) in group F. Our clinical results thus showed CDDP to have a greater effect than BLM, while HCR was shown to have a greater effect than CR. Conclusions. Preoperative therapy, especially using CDDP and hyperthermia, has improved thanks to recent advances in the treatment of esophageal cancer.

Original languageEnglish
Pages (from-to)S28-S34
JournalSurgery
Volume131
Issue number1 SUPPL.
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Esophageal Neoplasms
Esophagectomy
Chemoradiotherapy
Fever
Neoadjuvant Therapy
Therapeutics
Pharmaceutical Preparations
Fluorouracil
Survival Rate
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Ohga, T., Kimura, Y., Futatsugi, M., Miyazaki, M., Saeld, H., & Nozoe, T. (2002). Surgical and oncological advances in the treatment of esophageal cancer. Surgery, 131(1 SUPPL.), S28-S34. https://doi.org/10.1067/msy.2002.119291

Surgical and oncological advances in the treatment of esophageal cancer. / Ohga, Takefumi; Kimura, Yasue; Futatsugi, Motonori; Miyazaki, Mitsuhiro; Saeld, Hiroshi; Nozoe, Tadahiro.

In: Surgery, Vol. 131, No. 1 SUPPL., 01.01.2002, p. S28-S34.

Research output: Contribution to journalArticle

Ohga, T, Kimura, Y, Futatsugi, M, Miyazaki, M, Saeld, H & Nozoe, T 2002, 'Surgical and oncological advances in the treatment of esophageal cancer', Surgery, vol. 131, no. 1 SUPPL., pp. S28-S34. https://doi.org/10.1067/msy.2002.119291
Ohga T, Kimura Y, Futatsugi M, Miyazaki M, Saeld H, Nozoe T. Surgical and oncological advances in the treatment of esophageal cancer. Surgery. 2002 Jan 1;131(1 SUPPL.):S28-S34. https://doi.org/10.1067/msy.2002.119291
Ohga, Takefumi ; Kimura, Yasue ; Futatsugi, Motonori ; Miyazaki, Mitsuhiro ; Saeld, Hiroshi ; Nozoe, Tadahiro. / Surgical and oncological advances in the treatment of esophageal cancer. In: Surgery. 2002 ; Vol. 131, No. 1 SUPPL. pp. S28-S34.
@article{efb01db922aa4ed6ac3d02f71702eed0,
title = "Surgical and oncological advances in the treatment of esophageal cancer",
abstract = "Background. Chemoradiotherapy (CR) and hyperthermochemoradiotherapy (HCR) have been performed on numerous patients with esophageal cancer. These neoadjuvant therapies for esophageal cancer are done widely. The purpose of this study is to demonstrate the recent advances in surgical and oncological treatment. Methods. From 1967 to 2000, 847 patients who underwent an esophagectomy were classified into 4 groups according to the date of operation. Group 1 consisted of 110 patients who underwent an esophagectomy in the first 10-year period (1967-1976), group 2 consisted of 194 patients who had operations from 1977 to 1986, group 3 comprised 400 patients who had operations from 1987 to 1996, and group 4 comprised 143 patients who had operations from 1997 to 2000. From 1967 to 2000, 322 patients with neoadjuvant therapy and esophagectomy were classified into 6 groups according to the kinds of anitcancer drugs that were administered. Group A received regimen A, using BLM (5 mg iv) 6 times as the chemotherapeutic drug in the early period (1965-1990); group B received regimen B, using cis-diaminedichloroplatinum (CDDP) (40 mg/m2) 3 times as the chemotherapeutic drug in the second period (1990-1997); and group C received regimen C, using CDDP (40 mg/m2) and 5FU (250 mg/m2) daily in the most recent period (1997-2000). The HCR group was also divided into the following 3 groups: Group D, who received regimen A and hyperthermia 6 times in the early period; group E, who received regimen B and hyperthermia 6 times in the next period; and group F, who received regimen C and hyperthermia 6 times in the most recent period. The local response and the longterm results were investigated. Results. A complete removal of the primary tumor was achieved in 29{\%}, 39{\%}, 62{\%}, and 68{\%} of the patients in groups 1, 2, 3, and 4, respectively. The 30-day operative mortality rates were 11{\%}, 4{\%}, 1{\%}, and 0{\%} in groups 1, 2, 3, and 4, respectively. The 5-year survival rates for all patients in groups 1, 2, and 3 were 16.7{\%}, 19.2{\%}, and 44.4{\%}, respectively. The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4{\%}) in group A, 22 (73.3{\%}) in group B, 8 (66.7{\%}) in group C, 79 (63.7{\%}) in group D, 36 (73.5{\%}) in group E, and 12 (75.0{\%}) in group F. Our clinical results thus showed CDDP to have a greater effect than BLM, while HCR was shown to have a greater effect than CR. Conclusions. Preoperative therapy, especially using CDDP and hyperthermia, has improved thanks to recent advances in the treatment of esophageal cancer.",
author = "Takefumi Ohga and Yasue Kimura and Motonori Futatsugi and Mitsuhiro Miyazaki and Hiroshi Saeld and Tadahiro Nozoe",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/msy.2002.119291",
language = "English",
volume = "131",
pages = "S28--S34",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Surgical and oncological advances in the treatment of esophageal cancer

AU - Ohga, Takefumi

AU - Kimura, Yasue

AU - Futatsugi, Motonori

AU - Miyazaki, Mitsuhiro

AU - Saeld, Hiroshi

AU - Nozoe, Tadahiro

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background. Chemoradiotherapy (CR) and hyperthermochemoradiotherapy (HCR) have been performed on numerous patients with esophageal cancer. These neoadjuvant therapies for esophageal cancer are done widely. The purpose of this study is to demonstrate the recent advances in surgical and oncological treatment. Methods. From 1967 to 2000, 847 patients who underwent an esophagectomy were classified into 4 groups according to the date of operation. Group 1 consisted of 110 patients who underwent an esophagectomy in the first 10-year period (1967-1976), group 2 consisted of 194 patients who had operations from 1977 to 1986, group 3 comprised 400 patients who had operations from 1987 to 1996, and group 4 comprised 143 patients who had operations from 1997 to 2000. From 1967 to 2000, 322 patients with neoadjuvant therapy and esophagectomy were classified into 6 groups according to the kinds of anitcancer drugs that were administered. Group A received regimen A, using BLM (5 mg iv) 6 times as the chemotherapeutic drug in the early period (1965-1990); group B received regimen B, using cis-diaminedichloroplatinum (CDDP) (40 mg/m2) 3 times as the chemotherapeutic drug in the second period (1990-1997); and group C received regimen C, using CDDP (40 mg/m2) and 5FU (250 mg/m2) daily in the most recent period (1997-2000). The HCR group was also divided into the following 3 groups: Group D, who received regimen A and hyperthermia 6 times in the early period; group E, who received regimen B and hyperthermia 6 times in the next period; and group F, who received regimen C and hyperthermia 6 times in the most recent period. The local response and the longterm results were investigated. Results. A complete removal of the primary tumor was achieved in 29%, 39%, 62%, and 68% of the patients in groups 1, 2, 3, and 4, respectively. The 30-day operative mortality rates were 11%, 4%, 1%, and 0% in groups 1, 2, 3, and 4, respectively. The 5-year survival rates for all patients in groups 1, 2, and 3 were 16.7%, 19.2%, and 44.4%, respectively. The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 8 (66.7%) in group C, 79 (63.7%) in group D, 36 (73.5%) in group E, and 12 (75.0%) in group F. Our clinical results thus showed CDDP to have a greater effect than BLM, while HCR was shown to have a greater effect than CR. Conclusions. Preoperative therapy, especially using CDDP and hyperthermia, has improved thanks to recent advances in the treatment of esophageal cancer.

AB - Background. Chemoradiotherapy (CR) and hyperthermochemoradiotherapy (HCR) have been performed on numerous patients with esophageal cancer. These neoadjuvant therapies for esophageal cancer are done widely. The purpose of this study is to demonstrate the recent advances in surgical and oncological treatment. Methods. From 1967 to 2000, 847 patients who underwent an esophagectomy were classified into 4 groups according to the date of operation. Group 1 consisted of 110 patients who underwent an esophagectomy in the first 10-year period (1967-1976), group 2 consisted of 194 patients who had operations from 1977 to 1986, group 3 comprised 400 patients who had operations from 1987 to 1996, and group 4 comprised 143 patients who had operations from 1997 to 2000. From 1967 to 2000, 322 patients with neoadjuvant therapy and esophagectomy were classified into 6 groups according to the kinds of anitcancer drugs that were administered. Group A received regimen A, using BLM (5 mg iv) 6 times as the chemotherapeutic drug in the early period (1965-1990); group B received regimen B, using cis-diaminedichloroplatinum (CDDP) (40 mg/m2) 3 times as the chemotherapeutic drug in the second period (1990-1997); and group C received regimen C, using CDDP (40 mg/m2) and 5FU (250 mg/m2) daily in the most recent period (1997-2000). The HCR group was also divided into the following 3 groups: Group D, who received regimen A and hyperthermia 6 times in the early period; group E, who received regimen B and hyperthermia 6 times in the next period; and group F, who received regimen C and hyperthermia 6 times in the most recent period. The local response and the longterm results were investigated. Results. A complete removal of the primary tumor was achieved in 29%, 39%, 62%, and 68% of the patients in groups 1, 2, 3, and 4, respectively. The 30-day operative mortality rates were 11%, 4%, 1%, and 0% in groups 1, 2, 3, and 4, respectively. The 5-year survival rates for all patients in groups 1, 2, and 3 were 16.7%, 19.2%, and 44.4%, respectively. The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 8 (66.7%) in group C, 79 (63.7%) in group D, 36 (73.5%) in group E, and 12 (75.0%) in group F. Our clinical results thus showed CDDP to have a greater effect than BLM, while HCR was shown to have a greater effect than CR. Conclusions. Preoperative therapy, especially using CDDP and hyperthermia, has improved thanks to recent advances in the treatment of esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036160767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036160767&partnerID=8YFLogxK

U2 - 10.1067/msy.2002.119291

DO - 10.1067/msy.2002.119291

M3 - Article

C2 - 11821784

AN - SCOPUS:0036160767

VL - 131

SP - S28-S34

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1 SUPPL.

ER -